Handelsavisen
prelaunch
Companies Healthcare 308430.KQ
30
308430.KQ KOSDAQ Pharmaceuticals

308430.Kq

$18 250,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
-423,9 %
ROE
-33,2 %
Net margin
-389,4 %
Debt / equity
0,37
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

308430.KQ is a pharmaceutical company that develops and commercializes prescription drugs, primarily generating revenue through the sale of its therapeutic products in domestic and international markets.

Business. 308430.KQ is a pharmaceutical company that develops and commercializes prescription drugs, primarily generating revenue through the sale of its therapeutic products in domestic and international markets.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-33,2 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 308430.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 308430.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    308430.KQ is a pharmaceutical company that develops and commercializes prescription drugs, primarily generating revenue through the sale of its therapeutic products in domestic and international markets.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a debt-to-equity ratio of 0.37, indicating a relatively conservative leverage position compared to the industry median of 0.52. However, its liquidity position is weak, with negative free cash flow of -8.37 billion KRW and operating cash flow of -5.55 billion KRW, which is below the industry median of -1.2 billion KRW. The current ratio of 11.1 suggests strong short-term liquidity, but this is largely driven by high total assets rather than positive operating cash flow.

    Profitability metrics are severely negative, with a return on equity of -33.24% and return on assets of -21.52%, both well below the industry median of 12.4% and 8.7%, respectively. The company reported a net loss of 7.57 billion KRW and an operating loss of 8.24 billion KRW, which is a significant deviation from the industry's average net profit margin of 18.3%. These figures indicate a company in distress, with no clear path to profitability in the near term.

    Geographically, the company's revenue is concentrated in its domestic market, with no disclosed international segments. Segment-wise, the company operates as a single business unit, which increases its exposure to market-specific risks. The lack of diversification in both geography and product lines amplifies the impact of any adverse regulatory or economic developments.

    The company's growth trajectory is negative, with no disclosed revenue growth in the current fiscal year. The outlook for the next fiscal year is also uncertain, with no clear drivers of revenue expansion. The company's capital expenditure of -1.68 billion KRW suggests a reduction in investment, which may indicate a strategic shift or financial constraints. The absence of positive growth signals is a red flag for investors.

    Risk factors include a high probability of liquidity stress, as the company's operating cash flow is insufficient to cover its debt obligations. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the net cash position is negative after subtracting total debt. The company has not disclosed any recent equity issuances or dilution events, but the negative free cash flow suggests a potential need for external financing in the near term.

    Recent events include a significant operating loss and a net loss, which were disclosed in the latest financial filing. The company has not issued any press releases or earnings transcripts that indicate a turnaround strategy or new product launches. The absence of positive news or strategic initiatives further reinforces the perception of a company in decline.

    Key takeaways
    • The company is operating at a significant loss, with a return on equity of -33.24% and a return on assets of -21.52%.
    • Liquidity is strong on paper due to a current ratio of 11.1, but this is driven by high total assets rather than positive cash flow.
    • The company's capital structure is conservative, with a debt-to-equity ratio of 0.37, but its negative free cash flow of -8.37 billion KRW raises concerns about long-term sustainability.
    • The company lacks diversification in both geography and product lines, increasing its exposure to market-specific risks.
    • No recent strategic initiatives or positive financial developments have been disclosed, suggesting a lack of direction or momentum.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $18 250,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $22.79B
    Net cash
    -$6.46B
    Current ratio
    11.1
    Debt / equity
    0.4
    ROA
    -21.5%
    ROE
    -33.2%
    Cash conversion
    73.0%
    CapEx / revenue
    -86.3%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-423,9 %Bottom quartile
    Net Margin-389,4 %Bottom quartile
    ROE-33,2 %Bottom quartile
    Capex / Rev-86,3 %Bottom quartile
    D/E0,37Below median
    Cash Conv0,73Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 308430.KQ Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    308430.KQCanonical
    KOSDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage